DsiRNA was delivered in mice via IT injection using i-Fect. This added further support to the idea that the very potent DsiRNA coupled with a cationic delivery system that works in neurons is a very effective way to study the role of various genes in CNS function.
By Pete Shuster
|
Also posted in Synaptic Transmissiom, featured researchers, i-Fect Transfection Kits
|
Tagged 27mer DsiRNA, Add new tag, Delivering DsiRNA, Deliverying siRNA in vivo, Dr. Jeffrey Mogil, Dr. Mark Behlke, Dr. Philippe Sarret, Gene Expression, Gene Silencing Methods, intrathecal delivery of siRNA
|
October 1, 2008 – 7:52 pm
Just wanted to update you on my friends at Dicerna…from in vivo blog…
Wednesday, October 31, 2007
Dicerna Crashes RNAi Party
Life often imitates art, as the saying goes.
In “This Is Spinal Tap,” the classic rock and roll mockumentary chronicling the eponymous band, guitarist Nigel Tufnel famously brags that his amplifiers, unlike conventional ones that max out at [...]
September 29, 2008 – 1:05 pm
Shedding Light on New Pain Pathways
There is no joy in Painville. Our answer to pain is: “make it go away”! It spoils quality of life. The socio-economic costs for treatments, loss of productivity and absenteeism, are measured in billions USD$.
Today, moderate to severe pain is treated mostly with NSAIDs, narcotics or tricyclics (anti-depressants). Properly prescribed, [...]
By Pete Shuster
|
Also posted in Pain Research, People, featured researchers
|
Tagged APJ, CCR2, Chronic Pain, Dr. Philippe Sarret, i-Fect, morphine, Neurotensin Receptors, Nociceptive Pain, non-Narcotics, non-Opioid Pain Pathway, NTS2, Opioid Receptors, opioidergic-independent pathways, Pain Pathways, Pain Therapies, University of Sherbrooke
|
August 16, 2008 – 9:18 pm
15.07.2008 13:34
Dicerna Pharmaceuticals, a Second Generation RNA Interference Company, Completes Second Closing of Series A Financing; Unveils Strategic Focus
Dicerna Pharmaceuticals, Inc. (www.dicerna.com), an RNA interference company developing novel therapeutics utilizing proprietary Dicer Substrate Technology™, today announced a second closing of its Series A financing, receiving a total of $8.4 million in additional venture capital [...]
The DsiRNA story marches forward with yet another important publication. We will give you an opportunity to upload the fulltext article at the end of this posting.
Dr. Mark Behlke, Dr John Rossi and team have been gaining deeper understanding of the Mechanism of Dicer-substrate small-interfering RNA (DsiRNA) processing. This understanding is leading to better and [...]
Dr. Mark Behlke and 27mer DsiRNAs
I am pleased to be featuring Dr. Mark Behlke’s story as our first. This was an easy choice because our main characters, Mark and the 27mer DsiRNAs (Dicer Substrate Small Interfering RNAs), are rising stars in small interfering (siRNA) based research.
siRNAtechnology addresses the need for Biosciences Researchers and Clinicians [...]
By Pete Shuster
|
Also posted in People, Stories, featured researchers
|
Tagged 21mer siRNA, 27mer DsiRNA, Dicer Complex, Dicerna Pharmaceuticals, Dr. Dongho Kim, Dr. John Rossi, Dr. Mark Behlke, Dr. Philippe Sarret, Gene Expression, Gene Silencing, Integrated DNA Technologies, NTS2 Gene, Pain Modulation, RISC, University of Sherbrooke
|
